Details of the Drug

General Information of Drug (ID: DMCHWX1)

Drug Name
Nedosiran
Synonyms DCR-PHXC
Indication
Disease Entry ICD 11 Status REF
Primary hyperoxaluria type 1 5C51.20 Approved [1]
Hyperoxaluria 5C51.2 Phase 2 [2]
Drug Type
Small interfering RNA
Sequence
>Subunit 1
UCAGAUAAAAAGGACAACAUGG
>Subunit 2
AUGUUGUCCUUUUUAUCUGAGCAGCCGAAAGGCUGC
Cross-matching ID
UNII
13U9R5J3WL
DrugBank ID
DB17635
TTD ID
DZ8DF0

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
LDHA messenger RNA (LDHA mRNA) TTW76JE LDHA_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215842
2 ClinicalTrials.gov (NCT04580420) Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD (PHYOX7). U.S. National Institutes of Health.
3 Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098.